AKBA Akebia: Multiplikator Forward P/S

Akebia Corp (AKBA) - logo korporat

Raw material supply chain disruption risks have created volatility, as demonstrated by the forward EV/Revenue multiple. The current 0.60 figure determines the metric's magnitude, capturing the market's reaction to management's efforts to bring anemia drugs to market. Consequently, Akebia Therapeutics (AKBA) has focused on organic sales growth and distribution, eschewing merger deals.

AKBA akebia.com: Multiplikator Forward P/S ing interval 04.07.2022 - 18.11.2026

Akebia Therapeutics (AKBA) - rincian metrik lan laporan keuangan

- rega saham lan target rega konsensus:
Analisis komprehensif perusahaan:Akebia Therapeutics Inc AKBA
Sampel barang Akebia Corp

Defensive assets are selected based on criteria of low volatility and operational resilience. Akebia Therapeutics (AKBA) meets these requirements by minimizing capital expenditures through the outsourcing of drug production to contract manufacturing organizations. The company's forward P/S ratio compares the current market value of the business with expected revenue. The price action on this chart allows for an assessment of the issuer's valuation adequacy relative to its future cash flows.